Legend Biotech

Legend Biotech is a global biotechnology company founded in 2014, specializing in the development, manufacturing, and commercialization of cell therapies. With over 2,500 employees, it is recognized as the largest standalone cell therapy company. The company focuses on innovative immunotherapies, particularly CAR-T cell therapies, aimed at treating hematological malignancies, solid tumors, and infectious diseases. Legend Biotech offers end-to-end solutions that encompass cell therapy development, scalable manufacturing of autologous and allogeneic therapies, and global commercialization support. Its lead product, Carvykti, is a CAR-T therapy approved for relapsed/refractory multiple myeloma, demonstrating strong efficacy in late-line treatment. The company also has a pipeline of CAR-T therapies targeting various cancers, including gastric and lung cancers. With a strategic approach that includes global expansion and collaborations with academic and industry leaders, Legend Biotech is dedicated to advancing cancer care through innovative cell therapy solutions.